The market is up 5.5% over the last week and has risen 21% over the past year, with earnings forecast to grow by 17% annually. In such a robust market climate, investors often look for stocks that combine affordability with growth potential, making penny stocks an intriguing option. Although the term 'penny stocks' may seem outdated, these investments can still offer significant opportunities when rooted in strong financial health and stability.

Underneath we present a selection of stocks filtered out by our screen.

So-Young International (SY)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: So-Young International Inc. operates an online platform focused on consumption healthcare services in the People’s Republic of China, with a market cap of approximately $199.76 million.

Operations: The company's revenue is derived from its operations in China, totaling CN¥1.66 billion.

Market Cap: $199.76M

So-Young International, with a market cap of US$199.76 million, is navigating challenges typical for penny stocks. The company remains unprofitable, with losses increasing over the past five years at a rate of 61.4% annually; however, earnings are forecast to grow significantly by 103.22% per year. The management team is experienced, with an average tenure of 7.5 years and recent strategic leadership changes including the appointment of Ms. Nan Shen as CFO in August 2026 could bring fresh perspectives to financial operations. Despite high volatility and a negative return on equity (-16.41%), So-Young's short-term assets exceed both its short-term and long-term liabilities, providing some financial stability amidst uncertainty in its earnings trajectory.

Caribou Biosciences (CRBU)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on CRISPR genome-editing technologies, with a market cap of approximately $155.71 million.

Operations: The company's revenue is derived from developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies, totaling $11.20 million.

Market Cap: $155.71M

Caribou Biosciences, with a market cap of US$155.71 million, is navigating the complexities of the biotech sector as it remains unprofitable. Despite this, its inclusion in multiple Russell indices highlights growing investor interest. The company has a robust pipeline focused on CRISPR genome-editing technologies, with recent advancements in its vispa-cel and CB-011 therapies showing promising clinical trial results for relapsed or refractory conditions. Caribou's financial position is relatively stable; it is debt-free with short-term assets significantly exceeding liabilities, providing a cash runway sufficient for over a year under current conditions.

Honest Company (HNST)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: The Honest Company, Inc. is a personal care company that offers products for babies and adults, with a market cap of $428.21 million.

Operations: The company's revenue is derived entirely from its Personal Products segment, totaling $352.17 million.

Market Cap: $428.21M

The Honest Company, with a market cap of US$428.21 million, is navigating challenges in the personal care sector. Despite being unprofitable, it has maintained a positive free cash flow and holds no debt, ensuring a cash runway exceeding three years. Recent earnings show improved net income of US$10.69 million for Q2 2026 despite declining sales, prompting an upward revision of its annual revenue forecast to US$319-325 million. The company completed significant share buybacks totaling 6.56% for US$25 million and announced leadership changes to strengthen financial planning capabilities amidst its removal from several Russell indices in June 2026.

Next Steps

• Navigate through the entire inventory of 327 US Penny Stocks here.
• Looking For Alternative Opportunities? We've found 7 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.